Targeting Focal Adhesion Kinase and Resistance to mTOR Inhibition in Pancreatic Neuroendocrine Tumors

Journal of the National Cancer Institute

Volumn 107, Issue 8, 2015, Pages

  François, Rony A ^a   Maeng, Kyungah ^a   Nawab, Akbar ^a   Kaye, Frederic J ^a   Hochwald, Steven N ^b   Zajac Kaye, Maria ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; EVEROLIMUS; FOCAL ADHESION KINASE; FOCAL ADHESION KINASE INHIBITOR; MAMMALIAN TARGET OF RAPAMYCIN; PF 04554878; PROTEIN KINASE B; UNCLASSIFIED DRUG; FOCAL ADHESION KINASE 1; MTOR PROTEIN, HUMAN; ORGANIC COMPOUND; PROTEIN KINASE INHIBITOR; PTK2 PROTEIN, HUMAN; RAPAMYCIN; TARGET OF RAPAMYCIN KINASE; VS-6063;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; AUTOPHOSPHORYLATION; CANCER COMBINATION CHEMOTHERAPY; CARCINOMATOUS PERITONITIS; CELL PROLIFERATION; CELL VIABILITY; CLONOGENESIS; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG POTENTIATION; DRUG TARGETING; ENZYME ACTIVATION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; LYMPH NODE METASTASIS; MALE; MOUSE; NONHUMAN; PANCREATIC NEUROENDOCRINE TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; TUMOR GROWTH; TUMOR REGRESSION; TUMOR XENOGRAFT; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; CARCINOMA; CELL SURVIVAL; DRUG EFFECTS; DRUG RESISTANCE; DRUG SCREENING; GENE EXPRESSION REGULATION; METABOLISM; MOLECULARLY TARGETED THERAPY; NEUROENDOCRINE TUMORS; NONOBESE DIABETIC MOUSE; PANCREATIC NEOPLASMS; PERITONEAL NEOPLASMS; PROCEDURES; SCID MOUSE; SIGNAL TRANSDUCTION; TUMOR CELL LINE; UPREGULATION;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOMA; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; FEMALE; FOCAL ADHESION KINASE 1; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MICE; MICE, INBRED NOD; MICE, SCID; MOLECULAR TARGETED THERAPY; NEUROENDOCRINE TUMORS; ORGANIC CHEMICALS; PANCREATIC NEOPLASMS; PERITONEAL NEOPLASMS; PROTEIN KINASE INHIBITORS; SIGNAL TRANSDUCTION; SIROLIMUS; TOR SERINE-THREONINE KINASES; UP-REGULATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84939451665     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djv123     Document Type: Article

References (50)

1. Zhang J, Francois R, Iyer R, Seshadri M, Zajac-Kaye M, Hochwald SN. Current understanding of the molecular biology of pancreatic neuroendocrine tumors. J Natl Cancer Inst. 2013;105(14):1005-1017.
2. Jiao Y, Shi C, Edil BH, et al. DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science. 2011;331(6021):1199-1203.
3. Oberstein PE, Saif MW. Safety and efficacy of everolimus in adult patients with neuroendocrine tumors. Clin Med Insights Oncol. 2012;6:41-51.
4. Yao JC, Shah MH, Ito T, et al. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med. 2011;364(6):514-523.
5. Sankhala K, Giles FJ. Potential of mTOR inhibitors as therapeutic agents in hematological malignancies. Expert Rev Hematol. 2009;2(4):399-414.
6. Easton JB, Houghton PJ. Therapeutic potential of target of rapamycin inhibitors. Expert Opin Ther Targets. 2004;8(6):551-564.
7. Meric-Bernstam F, Gonzalez-Angulo AM. Targeting the mTOR signaling network for cancer therapy. J Clin Oncol. 2009;27(13):2278-2287.
8. Guo SS, Wu X, Shimoide AT, Wong J, Moatamed F, Sawicki MP. Frequent overexpression of cyclin D1 in sporadic pancreatic endocrine tumours. J Endocrinol. 2003;179(1):73-79.
9. Shah T, Hochhauser D, Frow R, Quaglia A, Dhillon AP, Caplin ME. Epidermal growth factor receptor expression and activation in neuroendocrine tumours. J Neuroendocrinol. 2006;18(5):355-360.
10. Ghayouri M, Boulware D, Nasir A, Strosberg J, Kvols L, Coppola D. Activation of the serine/theronine protein kinase akt in enteropancreatic neuroendocrine tumors. Anticancer Res. 2010;30(12):5063-5067.
11. Tuttle RL, Gill NS, Pugh W, et al. Regulation of pancreatic beta-cell growth and survival by the serine/threonine protein kinase Akt1/PKBalpha. Nat Med. 2001;7(10):1133-1137.
12. Miao G, Zhao Y, Li Y, et al. Basement membrane extract preserves islet viability and activity in vitro by up-regulating alpha3 integrin and its signal. Pancreas. 2013;42(6):971-976.
13. Zhao Y, Xu J, Wei J, Li J, Cai J, Miao G. Preservation of islet survival by upregulating alpha3 integrin signaling: The importance of 3-dimensional islet culture in basement membrane extract. Transplant Proc. 2010;42(10):4638-4642.
14. Fang Y, Wang L, Jin J, Zha X. Focal adhesion kinase affects the sensitivity of human hepatocellular carcinoma cell line SMMC-7721 to tumor necrosis factor-alpha/cycloheximide-induced apoptosis by regulating protein kinase B levels. Eur J Biochem. 2001;268(16):4513-4519.
15. Schmitz KJ, Grabellus F, Callies R, et al. High expression of focal adhesion kinase (p125FAK) in node-negative breast cancer is related to overexpression of HER-2/neu and activated akt kinase but does not predict outcome. Breast Cancer Res. 2005;7(2):R194-203.
16. Dasari VR, Kaur K, Velpula KK, et al. Downregulation of focal adhesion kinase (FAK) by cord blood stem cells inhibits angiogenesis in glioblastoma. Aging (Albany NY). 2010;2(11):791-803.
17. Crompton BD, Carlton AL, Thorner AR, et al. High-throughput tyrosine kinase activity profiling identifies FAK as a candidate therapeutic target in ewing sarcoma. Cancer Res. 2013;73(9):2873-2883.
18. Zheng Y, Gierut J, Wang Z, Miao J, Asara JM, Tyner AL. Protein tyrosine kinase 6 protects cells from anoikis by directly phosphorylating focal adhesion kinase and activating AKT. Oncogene. 2013;32(36):4304-4312.
19. Lee BY, Hochgrafe F, Lin HM, et al. Phosphoproteomic profiling identifies focal adhesion kinase as a mediator of docetaxel resistance in castrateresistant prostate cancer. Mol Cancer Ther. 2014;13(1):190-201.
20. Kang Y, Hu W, Ivan C, et al. Role of focal adhesion kinase in regulating YB-1-mediated paclitaxel resistance in ovarian cancer. J Natl Cancer Inst. 2013;105(19):1485-1495.
21. Owens LV, Xu L, Craven RJ, et al. Overexpression of the focal adhesion kinase (p125FAK) in invasive human tumors. Cancer Res. 1995;55(13):2752-2755.
22. Zhao J, Guan JL. Signal transduction by focal adhesion kinase in cancer. Cancer Metastasis Rev. 2009;28(1-2):35-49.
23. Hochwald SN, Nyberg C, Zheng M, et al. A novel small molecule inhibitor of FAK decreases growth of human pancreatic cancer. Cell Cycle. 2009;8(15):2435-2443.
24. Chatzizacharias NA, Giaginis C, Zizi-Serbetzoglou D, Kouraklis GP, Karatzas G, Theocharis SE. Evaluation of the clinical significance of focal adhesion kinase and SRC expression in human pancreatic ductal adenocarcinoma. Pancreas. 2010;39(6):930-936.
25. Kurenova E, Liao J, He DH, et al. The FAK scaffold inhibitor C4 disrupts FAK-VEGFR-3 signaling and inhibits pancreatic cancer growth. Oncotarget. 2013;4(10):1632-1646.
26. Zhang J, He DH, Zajac-Kaye M, Hochwald SN. A small molecule FAK kinase inhibitor, GSK2256098, inhibits growth and survival of pancreatic ductal adenocarcinoma cells. Cell Cycle. 2014;13(19):3143-3149.
27. Kim SJ, Park JW, Yoon JS, et al. Increased expression of focal adhesion kinase in thyroid cancer: immunohistochemical study. J Korean Med Sci. 2004;19(5):710-715.
28. Fujiwara Y, Monden M, Mori T, Nakamura Y, Emi M. Frequent multiplication of the long arm of chromosome 8 in hepatocellular carcinoma. Cancer Res. 1993;53(4):857-860.
29. Pan CC, Jong YJ, Chen YJ. Comparative genomic hybridization analysis of thymic neuroendocrine tumors. Mod Pathol. 2005;18(3):358-364.
30. Park JH, Lee BL, Yoon J, et al. Focal adhesion kinase (FAK) gene amplification and its clinical implications in gastric cancer. Hum Pathol. 2010;41(12):1664-1673.
31. Tonnies H, Toliat MR, Ramel C, et al. Analysis of sporadic neuroendocrine tumours of the enteropancreatic system by comparative genomic hybridisation. Gut. 2001;48(4):536-541.
32. Evers BM, Townsend CM Jr, Upp JR, et al. Establishment and characterization of a human carcinoid in nude mice and effect of various agents on tumor growth. Gastroenterology. 1991;101(2):303-311.
33. Kaku M, Nishiyama T, Yagawa K, Abe M. Establishment of a carcinoembryonic antigen-producing cell line from human pancreatic carcinoma. Gann. 1980;71(5):596-601.
34. Baroni MG, Cavallo MG, Mark M, Monetini L, Stoehrer B, Pozzilli P. Beta-cell gene expression and functional characterisation of the human insulinoma cell line CM. J Endocrinol. 1999;161(1):59-68.
35. Chou TC. Drug combination studies and their synergy quantification using the chou-talalay method. Cancer Res. 2010;70(2):440-446.
36. Schaller MD, Hildebrand JD, Shannon JD, Fox JW, Vines RR, Parsons JT. Autophosphorylation of the focal adhesion kinase, pp125FAK, directs SH2- dependent binding of pp60src. Mol Cell Biol. 1994;14(3):1680-1688.
37. Cobb MH, Hepler JE, Cheng M, Robbins D. The mitogen-activated protein kinases, ERK1 and ERK2. Semin Cancer Biol. 1994;5(4):261-268.
38. Franke TF, Hornik CP, Segev L, Shostak GA, Sugimoto C. PI3K/Akt and apoptosis: size matters. Oncogene. 2003;22(56):8983-8998.
39. Kaufmann SH, Desnoyers S, Ottaviano Y, Davidson NE, Poirier GG. Specific proteolytic cleavage of poly(ADP-ribose) polymerase: An early marker of chemotherapy-induced apoptosis. Cancer Res. 1993;53(17):3976-3985.
40. Hakem R, Hakem A, Duncan GS, et al. Differential requirement for caspase 9 in apoptotic pathways in vivo. Cell. 1998;94(3):339-352.
41. Vasseur B, Cadiot G, Zins M, et al. Peritoneal carcinomatosis in patients with digestive endocrine tumors. Cancer. 1996;78(8):1686-1692.
42. Elias D, Sideris L, Liberale G, et al. Surgical treatment of peritoneal carcinomatosis from well-differentiated digestive endocrine carcinomas. Surgery. 2005;137(4):411-416.
43. Cools J, Maertens C, Marynen P. Resistance to tyrosine kinase inhibitors: Calling on extra forces. Drug Resist Updat. 2005;8(3):119-129.
44. Otonkoski T, Banerjee M, Korsgren O, Thornell LE, Virtanen I. Unique basement membrane structure of human pancreatic islets: implications for betacell growth and differentiation. Diabetes Obes Metab. 2008;10(Suppl 4):119-127.
45. Aziz SA, Jilaveanu LB, Zito C, et al. Vertical targeting of the phosphatidylinositol-3 kinase pathway as a strategy for treating melanoma. Clin Cancer Res. 2010;16(24):6029-6039.
46. Halfdanarson TR, Rabe KG, Rubin J, Petersen GM. Pancreatic neuroendocrine tumors (PNETs): Incidence, prognosis and recent trend toward improved survival. Ann Oncol. 2008;19(10):1727-1733.
47. Yao JC, Hassan M, Phan A, et al. One hundred years after "carcinoid": Epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the united states. J Clin Oncol. 2008;26(18):3063-3072.
48. Franko J, Feng W, Yip L, Genovese E, Moser AJ. Non-functional neuroendocrine carcinoma of the pancreas: Incidence, tumor biology, and outcomes in 2,158 patients. J Gastrointest Surg. 2010;14(3):541-548.
49. Oberstein PE, Remotti H, Saif MW, Libutti SK. Pancreatic neuroendocrine tumors: Entering a new era. JOP. 2012;13(2):169-173.
50. O'Reilly KE, Rojo F, She QB, et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res. 2006;66(3):1500-1508.